Avinza Related Published Studies
Well-designed clinical trials related to Avinza (Morphine Extended Release)
Pharmacokinetics of an immediate and extended release oral morphine formulation utilizing the spheroidal oral drug absorption system in dogs. [2009.04]
Factors affecting dosing regimens of morphine sulfate extended-release (KADIAN) capsules. [2009.01]
Single-dose, extended-release epidural morphine (DepoDur) compared to conventional epidural morphine for post-cesarean pain. [2007.07]
A randomized, open-label, multicenter trial comparing once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for the treatment of chronic, moderate to severe low back pain: improved physical functioning in the ACTION trial. [2007.01]
A randomized, open-label study of once-a-day AVINZA (morphine sulfate extended-release capsules) versus twice-a-day OxyContin (oxycodone hydrochloride controlled-release tablets) for chronic low back pain: the extension phase of the ACTION trial. [2006.11]
Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain. [2006.08]
Single-dose extended-release epidural morphine for pain after hip arthroplasty. [2006.07]
The ACTION study: a randomized, open-label, multicenter trial comparing once-a-day extended-release morphine sulfate capsules (AVINZA) to twice-a-day controlled-release oxycodone hydrochloride tablets (OxyContin) for the treatment of chronic, moderate to severe low back pain. [2006.05]
Treatment of chronic moderate-to-severe non-malignant pain with polymer-coated extended-release morphine sulfate capsules. [2006.03]
Evaluation of a single-dose, extended-release epidural morphine formulation for pain after knee arthroplasty. [2006.02]
Pharmacokinetics of morphine and plasma concentrations of morphine-6-glucuronide following morphine administration to dogs. [2005.08]
Forty-eight hours of postoperative pain relief after total hip arthroplasty with a novel, extended-release epidural morphine formulation. [2005.05]
Single-dose, sustained-release epidural morphine in the management of postoperative pain after elective cesarean delivery: results of a multicenter randomized controlled study. [2005.04]
A comparison of Depodur, a novel, single-dose extended-release epidural morphine, with standard epidural morphine for pain relief after lower abdominal surgery. [2005.04]
Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. [2002.04]
Pharmacokinetic evaluation of a sprinkle-dose regimen of a once-daily, extended-release morphine formulation. [2002.02]
Bioequivalence study of two morphine extended release formulations after multiple dosing in healthy volunteers. [1999.03]
Well-designed clinical trials possibly related to Avinza (Morphine Extended Release)
Relationship between rate of infusion and reinforcing strength of oxycodone in humans. [2009.07]
The pain quality response profile of oxymorphone extended release in the treatment of low back pain. [2009.02]
Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use. [2009.02]
Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain. [2008.03]
Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis. [2007.05]
Premedication with controlled-release oxycodone does not improve management of postoperative pain after day-case gynaecological laparoscopic surgery. [2007.02]
Efficacy and Safety of OPANA ER (Oxymorphone Extended Release) for Relief of Moderate to Severe Chronic Low Back Pain in Opioid-Experienced Patients: A 12-Week, Randomized, Double-blind, Placebo-controlled Study. [2007.02]
A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. [2007.01]
A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee. [2006.03]
Oxymorphone Extended-Release Tablets Relieve Moderate to Severe Pain and Improve Physical Function in Osteoarthritis: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Trial. [2005.09]
Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials. [2005.06]
Clinical pharmacology and pharmacokinetics of once-daily hydromorphone hydrochloride extended-release capsules. [2005.05]
Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. [2005.03]
Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. [2005.01]
Efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty. [2004.07]
Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. [2004.06]
Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. [2004.04]
Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. [2002.10]
Other research related to Avinza (Morphine Extended Release)
Extended-release epidural morphine (DepoDur) following epidural bupivacaine in patients undergoing lower abdominal surgery: a randomized controlled pharmacokinetic study. [2009.07]
Pharmacokinetics of extended-release epidural morphine sulfate: pooled analysis of six clinical studies. [2009.06.01]
Extended-release epidural morphine (DepoDur): review and safety analysis. [2008.11]
Extended-release, once-daily morphine (Avinza) for the treatment of chronic nonmalignant pain: effect on pain, depressive symptoms, and cognition. [2008.11]
Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain. [2008.09]
Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines. [2008.07]
Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). [2008.07]
Morphine sulfate extended-release capsules for the treatment of chronic, moderate-to-severe pain. [2008.06]
Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception. [2008.04.14]
Effect of concomitant ingestion of alcohol on the in vivo pharmacokinetics of KADIAN (morphine sulfate extended-release) capsules. [2008.04]
KADIAN (morphine sulfate extended-release) capsules for treatment of chronic, moderate-to-severe, nonmalignant pain. [2008.03]
Effect of Concomitant Ingestion of Alcohol on the In Vivo Pharmacokinetics of KADIAN (Morphine Sulfate Extended-Release) Capsules. [2008.01.15]
Administration of morphine sulfate extended-release capsules via gastrostomy: dissolution study and case reports. [2007.10]
Diflunisal salts of bupivacaine, lidocaine and morphine. Use of the common ion effect for prolonging the release of bupivacaine from mixed salt suspensions in an in vitro dialysis model. [2007.07]
Sleep improves when patients with chronic OA pain are managed with morning dosing of once a day extended-release morphine sulfate (AVINZA): findings from a pilot study. [2007.05]
DepoDur extended-release epidural morphine: reshaping postoperative care. What perioperative nurses need to know. [2007.03]
Sensitization to the conditioned rewarding effects of morphine modulates gene expression in rat hippocampus. [2007.02]
A study of AVINZA (morphine sulfate extended-release capsules) for chronic moderate-to-severe noncancer pain conducted under real-world treatment conditions--the ACCPT Study. [2006.12]
Single-dose extended-release epidural morphine for pain following hip arthroplasty. [2006.09]
Extended-release lipid-foam encapsulated epidural morphine: clinical efficacy and safety precautions. [2005.05]
Reticuline exposure to invertebrate ganglia increases endogenous morphine levels. [2004.10]
Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain. [2004.06]
Avinza - 24-h sustained-release oral morphine therapy. [2004.02]
A single dose of liposome-encapsulated oxymorphone or morphine provides long-term analgesia in an animal model of neuropathic pain. [2003.06]
Effects of cold stress on morphine-induced nitric oxide production and mu-opiate receptor gene expression in Mytilus edulis pedal ganglia. [2003.02]
Avinza Elan. [2002.09]
Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain. [2002.04]
Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. [1999.05]
[Cancer pain: beneficial effect of ketamine addition to spinal administration of morphine-clonidine-lidocaine mixture] [1996]
Extended-release formulation of morphine for subcutaneous administration. [1993]
Potential cost-avoidance with oral extended-release morphine sulfate tablets versus morphine sulfate solution. [1991.01]
Other possibly related research studies
Are one or two dangerous? Opioid exposure in toddlers. [2005.07]
Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study. [2005.03]
Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. [2005.01]
Emerging techniques for postoperative analgesia in orthopedic surgery. [2004.05]
Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats. [2003.11]
Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. [2002.05]
Respiratory depression following administration of intrathecal bupivacaine to an opioid-dependent patient. [1998.06]
Nurses' knowledge about equianalgesia and opioid dosing. [1997.06]
In vitro and in vivo studies of subcutaneous hydromorphone implants designed for the treatment of cancer pain. [1996.05]
The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction. [1995.06]
Stimulus-induced depletion of pro-enkephalins, oxytocin and vasopressin and pro-enkephalin interaction with posterior pituitary hormone release in vitro. [1994.12]
Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain. [2006.01]
Development of an oral sustained release drug delivery system utilizing pH-dependent swelling of carboxyvinyl polymer. [2006.04.10]
Rates of adverse events of long-acting opioids in a state Medicaid program. [2007.06]
Clinical Trial Results with OROS((R)) Hydromorphone. [2007.02]
Emerging treatment modalities: balancing efficacy and safety. [2007.03.15]
The metamorphosis of hydromorphone. [2005.07]
Extended-duration agents for perioperative pain management. [2007.02]
Oral extended-release oxymorphone: a new choice for chronic pain relief. [2007.07]
Use of oral oxymorphone in the elderly. [2007.05]
Oral oxymorphone for pain management. [2007.07]
Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study. [2007.10]
Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone. [2007.10]
Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. [2007.08]
[An attitude survey on the medical use of narcotics for cancer pain relief] [2007.12]
Putting evidence into practice: evidence-based interventions for cancer-related dyspnea. [2008.04]
Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone. [2008.06]
Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review. [2008.05]
Respiratory depression after neuraxial opioids in the obstetric setting. [2008.09]
Internet-based survey of nonmedical prescription opioid use in the United States. [2008.07]
Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain. [2008.10]
Markers of abuse liability of short- vs long-acting opioids in chronic pain patients: a randomized cross-over trial. [2009.11]
Long-term safety, tolerability, and efficacy of OROS hydromorphone in patients with chronic pain. [2009.03]
FDA approvals of generic drugs: impact on the diversion of opioid analgesics with a potential for abuse. [2009.03]
Successful treatment of refractory pudendal neuralgia with pulsed radiofrequency. [2009.05]
|
